vimarsana.com

Sample Size Re Estimation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BELLUS Health Reports Second Quarter 2021 Financial Results and Business Highlights

The Phase 2b SOOTHE and Phase 2a BLUEPRINT clinical trials are on track, with topline results expected in Q4 2021 - BELLUS Health Inc. a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the second quarter ending June 30, 2021. PROGRAM AND CORPORATE .

Aligning Commercial Strategy And Statistical Design

Aligning Commercial Strategy And Statistical Design Da Volterra wanted to maximize the power of their clinical trial for scenarios with a smaller treatment effect, and were contemplating a Sample Size Re-estimation design. Unfortunately, with a strict enrollment limit of 1,100 patients, this particular study design produced only marginal gains in power over the fixed sample size design. The Sponsor’s Chief Medical Officer was not content to risk the success of their new drug on a suboptimal trial design. By working with Cytel’s statistical consultants and their powerful new software platform Solara, Da Volterra was able to maximize the chance of a successful trial result with precise insight into the tradeoffs in speed, savings and success with a simple, low-risk trial design identified within hours.

Sponsor Discovers Unique Study Design That De-Risks Clinical Trial And Optimizes Commercial Strategy

Sponsor Discovers Unique Study Design That De-Risks Clinical Trial And Optimizes Commercial Strategy
clinicalleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from clinicalleader.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.